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Tau positron emission tomography (PET) would be useful for the diagnosis of 
Alzheimer’s disease (AD) and non-AD tauopathies, such as progressive supranuclear palsy 
(PSP), corticobasal degeneration (CBD), and some variants of frontotemporal lobar 
degeneration (FTLD). [18F]THK-5351 was one of the first-generation tau PET radiotracers 
that was designed originally to detect tau aggregates in the form of PHF-tau in AD1). Clinical 
PET studies in PSP and CBS patients have demonstrated prominent [18F]THK-5351 retention 
in the midbrain and basal ganglia where tau pathology was observed frequently at autopsy2,3). 
However, recent studies have suggested the existence of off-target binding to monoamine 
oxidase-B (MAO-B). Selegiline, a selective irreversible MAO-B inhibitor, substantially 
reduced [18F]THK-5351 binding in the brain of patients with PSP as well as AD4). In an 
autopsy case of AD, [18F]THK-5351 PET signal reflects the combination of tau pathology 
and reactive astrocytes in the AD brain5). However, what an [18F]THK-5351 PET signal 
reflects in the PSP brain remains unclear. We examined imaging-pathology correlation in two 
autopsy-confirmed PSP patients who showed prominent tracer retention on an antemortem 
[18F]THK-5351 PET scan. 
 
Materials and methods 
PET images were acquired using an Eminence STARGATE PET scanner. After 
intravenous injection of [18F]THK-5351 (185 MBq) or [11C]PiB (296 MBq), dynamic PET 
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images were obtained for 60 ([18F]THK-5351) or 70 ([11C]PiB) min. T1-weighted magnetic 
resonance images (MRI) were obtained using a SIGNA 1.5-Tesla machine. Standardized 
uptake value (SUV) images of [18F]THK-5351 (40–60 min after injection) and [11C]PiB (50–
70 min after injection) were obtained. The regional SUV-to-cerebellar cortex SUV ratio 
(SUVR) was used as an index of tracer retention. SPM12 software and PMOD Ver. 3.7 
software were used for image analysis. 
The left hemisphere of the brain was immersed in 10% formalin for histology. The 
brain portions were frozen for biochemical analyses and unfixed tissue-based assays. Tissue 
sections of paraffin-embedded blocks were stained with Luixol fast blue and hematoxylin-
eosin. Selected sections were stained with anti-tau AT8, anti-β-amyloid 4G8, anti-α-synuclein 
P-syn/81A, anti-TDP43 pS409/410–1, and anti-GFAP 6F2 antibodies.  
Quantification of tau and glial fibrillary acidic protein (GFAP) immunoreactivity, in vitro 
autoradiography of [18F]THK-5351 and [3H]THK-5351, semiquantification of PHF-tau by 
immunoblotting, and quantification of MAO-B and GFAP by enzyme-linked immunosorbent 




An 84-year-old male presented with memory disturbance and disorientation. One year 
later, standing and gait became unstable with progression of extrapyramidal signs and PSP 
was diagnosed clinically. PET scans were performed 2 years after the diagnosis of PSP. At 
the time of the PET scan, he was bedridden and the Mini-Mental State Examination (MMSE) 
score was 1 of 30. The PSP rating scale score was 82. A brain MRI showed a typical 
“hummingbird sign”. He died of aspiration pneumonia 295 days after the PET scan.  
Subject 2 
A 73-year-old male presented with memory disturbance. Mild cognitive impairment 
was diagnosed clinically 3 years after the first symptoms appeared. He gradually presented 
with speech impairment, stereotypical behavior, and change of food preference, and 
progressive nonfluent aphasia (PNFA) was diagnosed. One year later, he presented with 
unstable gait and was prone to falls. At the PET scan, he was bedridden and the MMSE score 
was 1 of 30. An MRI showed diffuse brain atrophy prominent in the right anterior temporal, 





[18F]THK-5351 and [11C]PiB PET scans 
Figure 1 shows the [18F]THK-5351 PET images from the two subjects. Images from 
a cognitively normal individual are shown for comparison at the bottom. Subject 1 showed 
significant [18F]THK-5351 retention in the globus pallidus and midbrain. Mild tracer 
retention was observed also in the other cortices, including parahippocampal and inferior 
temporal gyri. Subject 2 showed prominent [18F]THK-5351 retention in the parahippocampal 
and inferior temporal gyri, as well as the globus pallidus and midbrain. No remarkable 
retention of [11C]PiB was observed in the neocortex in both of the subjects. 
 
Neuropathological examination 
Brain weight in subject 1 was 1580 g. Autopsy revealed severe atrophy in the 
midbrain tegmetum, pons, subthalamic nucleus, and relatively mild atrophy in the frontal 
cortex, but not in the basal ganglia. Neuropathological examination revealed tau pathology 
in neuronal and glial cells consistent with PSP. Globose tangles were observed in the midbrain, 
pons, medulla, subthalamic nucleus, and nucleus basalis of Meynert. Moderate numbers of 
tufted astrocytes were observed also in the amygdala, motor cortex, and superior frontal gyrus. 
Neurofibrillary tangles were observed in the area which corresponded to age-related Braak 
stage II. The tau immunoreactivity density appeared greatest in the medial temporal regions, 
followed by the basal ganglia and frontal cortex. Gliosis and neuronal loss were observed 
also in the substantia nigra. However, amyloid-β, α-synuclein, and TDP-43 pathology were 
absent in this case. 
Brain weight in subject 2 was 920 g. Autopsy revealed atrophy in the temporal lobes, 
midbrain, pons, globus pallidus, hypothalamic nucleus, and cerebellar dentate nucleus. There 
was neuronal loss in the pigmented neurons of the substantia nigra and locus coeruleus. AT8 
immunostaining revealed abundant tau burden, including neurofibrillary tangles, globose 
tangles, tufted astrocytes, coiled bodies, and neuropil threads in the temporal, cingulate, 
frontal, striatum, globus pallidus, and subthalamic nucleus. In addition, thorn-shaped 
astrocytes, typical in aging-related tau astrogliopathy, were observed in the temporal lobe 
gray and white matter. Sparse amyloid plaques were observed. Both α-synuclein and TDP-
43 pathology were absent in this case. Gliosis was severe in the bilateral hippocampus and 
amygdala. Astrocytosis with neuronal loss was prominent in the temporal cortex, followed 
by the frontal and cingulate cortices. These tau lesions were composed of 4-repeat tau. These 
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results were consistent with atypical PSP, which was diagnosed as PSP-FTD. 
 
In vivo–in vitro correlation analyses 
Biochemical analysis revealed the presence of 4-repeat tau in both cases. In subject 1, 
sarkosyl-insoluble tau was high in the parahippocampal gyrus and hippocampus, moderate 
in the globus pallidus and putamen, and low in other areas. The parahippocampal gyrus 
contained 3- and 4-repeat tau, suggesting that they are age-related tau. AT8 
immunohistochemistry was positive in the brain sections from the same tissue. In subject 1, 
in vivo [18F]THK-5351 binding was correlated significantly with sarkosyl-insoluble tau 
levels determined by Western blot analysis (r = 0.67, P = 0.039). In addition, we found strong 
correlations between in vivo [18F]THK-5351 binding and MAO-B levels (r = 0.78, P = 
0.0096), between in vivo [18F]THK-5351 binding and GFAP level (r = 0.67, P = 0.039). In 
vitro [3H]THK-5351 binding assay using brain homogenates also demonstrated a strong 
correlation between in vivo [18F]THK-5351 retention and in vitro tracer binding in subject 1 
(r = 0.92, P = 0.005). Tau and GFAP immunoreactivities in the brain sections were measured 
quantitatively for correlation analysis between in vivo tracer retention and histopathology. 
We observed positive correlation trends between in vivo [18F]THK-5351 retention and tau 
loads (r = 0.48, P = 0.06), and between in vivo [18F]THK-5351 retention and GFAP 
immunoreactivity (r = 0.49, P = 0.05). In subject 2, in vivo [18F]THK-5351 binding was 
correlated significantly with tau-immunohistochemistry using AT8 antibody (r = 0.48, P = 
0.037). Furthermore, in vivo [18F]THK-5351 retention was correlated positively with the 
density of GFAP immunoreactive astrocytes (r = 0.64, P = 0.0033). 
 
In vitro autoradiography 
In vitro autoradiography of [18F]THK-5351 in frozen sections demonstrated high 
tracer binding in the globus pallidus as well as putamen in subject 1 and in the frontal cortex 
in subject 2, which was consistent with in vivo PET results. These bindings were displaced 
completely after treatment with MAO-B inhibitor, Lazabemide. The spatial pattern of 
[18F]THK-5351 binding was similar to that of MAO-B immunostaining, suggesting that the 
target of [18F]THK-5351 binding was MAO-B positive astrogliosis rather than the tau 





Tremendous efforts have been made to develop tau-selective PET 
radiopharmaceuticals. The first-generation tau PET tracers, such as [11C]PBB3, [18F]AV1451, 
and [18F]THK-5351, showed nonnegligible off-target binding. In this study, we expanded the 
imaging-pathology correlation analysis to autopsy-confirmed PSP cases showing two 
different clinical phenotypes, Richardson syndrome (PSP-RS) and PNFA. 
A patient with PSP-RS showed the spatial distribution of [18F]THK-5351 retention 
which was similar to cases of classic PSP-RS. Postmortem examination of this patient 
confirmed the existence of 4-repeat tau aggregates in these regions. However, imaging-
pathology correlation analysis indicated a significant correlation between in vivo [18F]THK-
5351 retention and MAO-B level. Furthermore, in vitro autoradiography demonstrated that 
[18F]THK-5351 binding in the globus pallidus was displaced by the MAO-B inhibitor, 
suggesting that [18F]THK-5351 mainly binds to the MAO-B rather than the 4-repeat tau 
aggregates. In our previous study using paraffin-embedded fixed brain sections, we observed 
specific binding of [18F]THK-5351 to tufted astrocytes and neurofibrillary tangles in the PSP 
brain2). However, the fixation of tissues and use of alcohol in the differentiation process may 
affect the tracer binding in in vitro autoradiography experiments. In this study, we performed 
in vitro autoradiographs of fresh-frozen sections without using alcohol and found a 
substantial amount of tracer binding to MAO-B. Fresh-frozen section results showed good 
agreement with antemortem [18F]THK-5351 PET analysis. These results highlighted the 
importance of appropriate experimental procedures in the validation of PET 
radiopharmaceuticals. 
We observed a significant correlation between tau pathology and GFAP in both of our 
subjects. A postmortem study reported that the density of GFAP correlated with that of 
neurofibrillary tangles, but not with tufted astrocytes in PSP, suggesting the greater 
contribution of neurofibrillary tangles to astrogliosis in PSP7). MAO-B is expressed 
dominantly in the mitochondrial outer membrane of astrocytes. Since elevation of MAO-B 
levels in the brain has been implicated in several neurodegenerative diseases, MAO-B is an 
attractive target as a molecular imaging marker of astrogliosis. Our study strongly supported 
that [18F]THK-5351 PET dominantly reflected the binding to MAO-B in patients with PSP. 
Therefore, [18F]THK-5351 PET would be useful for in vivo assessment of astrogliosis in PSP. 
Future research should proceed with development of PET tracers for selective detection of 
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Figure 1.  [18F]THK-5351 PET images from two study subjects and a 
cognitively normal subject. 
